| Roche Pharma (Schweiz) AG - Hemlibra 105mg/0.7ml, Injektionslösung |
| 66694 | | 03 | | Hemlibra 105mg/0.7ml | | Injektionslösung | | B02BX06 | | Emicizumab | | 06.11.2018 | | |
|
| Composition |
| emicizumabum 105 mg, histidinum, acidum asparticum ad pH, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. |
| Packungsbestandteile |
| Solution injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Emicizumabum | 105mg / 0.7ml |
| | BAG: Principe actif | Concentr. |
|---|
| Emicizumabum | 105 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Acidum Asparticum ad Ph | | | Arginine | | | Histidine | | | Poloxamer | 188 |
| |
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | 6488.09 | 6697.80 | A | LS | Oui |
|
